Published in J Infect Dis on July 01, 2010
Long-term therapy of chronic delta hepatitis with peginterferon alfa. Aliment Pharmacol Ther (2014) 2.19
APASL consensus statements and recommendation on treatment of hepatitis C. Hepatol Int (2016) 0.96
The influence of hepatitis B virus on antiviral treatment with interferon and ribavirin in Asian patients with hepatitis C virus/hepatitis B virus coinfection: a meta-analysis. Virol J (2012) 0.88
Long-term effect of interferon plus ribavirin on hepatitis B surface antigen seroclearance in patients dually infected with hepatitis B and C viruses. PLoS One (2011) 0.79
Sequential immunological analysis of HBV/HCV co-infected patients during Peg-IFN/RBV therapy. J Gastroenterol (2012) 0.78
Personalized Therapy of Chronic Hepatitis C and B Dually Infected Patients With Pegylated Interferon Plus Ribavirin: A Randomized Study. Medicine (Baltimore) (2015) 0.77
Practical approach in hepatitis B e antigen-negative individuals to identify treatment candidates. World J Gastroenterol (2014) 0.76
Updates on the treatment and outcomes of dual chronic hepatitis C and B virus infection. World J Gastroenterol (2014) 0.76
MicroRNA-122 as a predictor of HBsAg seroclearance in hepatitis B and C dual infected patients treated with interferon and ribavirin. Sci Rep (2016) 0.75
HBsAg Quantification in Clinical Practice. J Clin Exp Hepatol (2012) 0.75
Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA (2006) 10.58
A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med (2006) 7.35
Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med (2002) 6.20
Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med (2004) 5.40
Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int (2008) 5.25
Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma. Hepatol Int (2010) 5.02
Chemotherapy-induced hepatitis B reactivation in lymphoma patients with resolved HBV infection: a prospective study. Hepatology (2014) 3.92
Rapid growth of a hepatocellular carcinoma and the driving mutations revealed by cell-population genetic analysis of whole-genome data. Proc Natl Acad Sci U S A (2011) 3.80
Global control of hepatitis B virus infection. Lancet Infect Dis (2002) 3.74
A systematic review of hepatitis C virus epidemiology in Asia, Australia and Egypt. Liver Int (2011) 3.69
Relation of an interleukin-10 promoter polymorphism to graft-versus-host disease and survival after hematopoietic-cell transplantation. N Engl J Med (2003) 3.57
Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology (2010) 3.57
Nomograms for risk of hepatocellular carcinoma in patients with chronic hepatitis B virus infection. J Clin Oncol (2010) 3.55
Statements from the Taormina expert meeting on occult hepatitis B virus infection. J Hepatol (2008) 3.50
Hepatitis B virus genotype and DNA level and hepatocellular carcinoma: a prospective study in men. J Natl Cancer Inst (2005) 3.48
Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study. J Clin Oncol (2013) 3.45
Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): development and validation of a predictive score. Lancet Oncol (2011) 3.32
Associations between hepatitis B virus genotype and mutants and the risk of hepatocellular carcinoma. J Natl Cancer Inst (2008) 3.27
Chronic hepatitis C virus infection increases mortality from hepatic and extrahepatic diseases: a community-based long-term prospective study. J Infect Dis (2012) 3.22
Eltrombopag before procedures in patients with cirrhosis and thrombocytopenia. N Engl J Med (2012) 3.20
Decreased incidence of hepatocellular carcinoma in hepatitis B vaccinees: a 20-year follow-up study. J Natl Cancer Inst (2009) 3.19
Relationship between androgen levels and blood pressure in young women with polycystic ovary syndrome. Hypertension (2007) 3.15
Pegylated interferon-alpha-2a plus ribavirin for treatment-naive Asian patients with hepatitis C virus genotype 1 infection: a multicenter, randomized controlled trial. Clin Infect Dis (2008) 3.01
Basal core promoter mutations of hepatitis B virus increase the risk of hepatocellular carcinoma in hepatitis B carriers. Gastroenterology (2003) 2.97
Pegylated interferon-α2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 1 receiving hemodialysis: a randomized trial. Ann Intern Med (2013) 2.84
Evaluation of abdominal ultrasonography mass screening for hepatocellular carcinoma in Taiwan. Hepatology (2014) 2.79
Transmission of occult hepatitis B virus by transfusion to adult and pediatric recipients in Taiwan. J Hepatol (2005) 2.58
Mother-to-infant transmission of hepatitis B virus infection: significance of maternal viral load and strategies for intervention. J Hepatol (2013) 2.58
A revisit of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in non-Hodgkin's lymphoma: a randomized trial. Hepatology (2008) 2.55
How common is non-alcoholic fatty liver disease in the Asia-Pacific region and are there local differences? J Gastroenterol Hepatol (2007) 2.48
Metabolic factors and risk of hepatocellular carcinoma by chronic hepatitis B/C infection: a follow-up study in Taiwan. Gastroenterology (2008) 2.46
Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2005 update. Liver Int (2005) 2.46
Clinical characteristics and prognostic factors of splenic abscess: a review of 67 cases in a single medical center of Taiwan. World J Gastroenterol (2006) 2.41
High levels of hepatitis B surface antigen increase risk of hepatocellular carcinoma in patients with low HBV load. Gastroenterology (2012) 2.36
Neither diabetes mellitus nor overweight is a risk factor for hepatocellular carcinoma in a dual HBV and HCV endemic area: community cross-sectional and case-control studies. Am J Gastroenterol (2010) 2.32
Hepatitis C virus induces a mutator phenotype: enhanced mutations of immunoglobulin and protooncogenes. Proc Natl Acad Sci U S A (2004) 2.30
Treatment of chronic hepatitis C in Asia: when East meets West. J Gastroenterol Hepatol (2009) 2.23
Pre-S deletion and complex mutations of hepatitis B virus related to advanced liver disease in HBeAg-negative patients. Gastroenterology (2007) 2.20
P53 gene and Wnt signaling in benign neoplasms: beta-catenin mutations in hepatic adenoma but not in focal nodular hyperplasia. Hepatology (2002) 2.18
Steroid-free chemotherapy decreases risk of hepatitis B virus (HBV) reactivation in HBV-carriers with lymphoma. Hepatology (2003) 2.15
Living donor liver transplantation: the Asian perspective. Transplantation (2014) 2.13
Signal transducer and activator of transcription 3 is a major kinase-independent target of sorafenib in hepatocellular carcinoma. J Hepatol (2011) 2.12
Ultrafine titanium dioxide particles in the absence of photoactivation can induce oxidative damage to human bronchial epithelial cells. Toxicology (2005) 2.12
Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B. Gastroenterology (2007) 2.11
Correlation between ultrasonographic and pathologic diagnoses of hepatitis B and C virus-related cirrhosis. J Gastroenterol (2003) 2.09
Expression and prognostic role of tumor suppressor gene PTEN/MMAC1/TEP1 in hepatocellular carcinoma. Cancer (2003) 2.09
Hepatocellular carcinoma surveillance at 4- vs. 12-month intervals for patients with chronic viral hepatitis: a randomized study in community. Am J Gastroenterol (2013) 2.06
Interferon therapy in HBeAg positive chronic hepatitis reduces progression to cirrhosis and hepatocellular carcinoma. J Hepatol (2006) 2.03
The clinical implications of hepatitis B virus genotype: Recent advances. J Gastroenterol Hepatol (2011) 2.02
Reduced toll-like receptor 9 expression on peripheral CD14+ monocytes of chronic hepatitis B patients and its restoration by effective therapy. Antivir Ther (2014) 1.99